NCT03564691
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Recruiting
Phase 1
Drug Category: Therapeutic Antibody, Immunotherapy
Key Eligibility Criteria:
Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases:
Additional Notes:
Exclusions: Patient has known untreated central nervous system (i.e., brain and/or spinal cord) metastases or carcinomatous meningitis
https://ClinicalTrials.gov/show/NCT03564691